Mylan to Commercialize Atomo Dx HIV Self-Tests in Low-, Middle-Income Nations

Sep 24, 2018

NEW YORK (360Dx) — Atomo Diagnostics has signed an agreement to commercialize its CE-marked HIV self-tests in low- and middle-income nations with Mylan Pharmaceuticals, the companies announced today.

Atomo's tests use the firm's AtomoRapid technology to detect the presence of HIV antibodies from a finger prick of blood and provides results within 15 minutes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Featured White Papers

Advancing Patient Care and Aiding Diagnosis at the Point of Care

Molecular Tests Provide a Better Alternative to Stool Culture for GI Cases

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Mar

19

Featured Webinar

One Test May Not Fit All: Evaluation of Point-of-Care Assays for Influenza Testing

In this webinar, Dr. Matthew Faron, a pathologist from the Medical College of Wisconsin, will share results of a comparison study of three rapid influenza assays.

Mar

20

Featured Webinar

A New Multiplex Syndromic System For Respiratory Diagnosis And Improved Patient Care

This webinar will discuss how a new multiplexed testing system can help physicians rapidly diagnose acute respiratory infections in the near-patient setting.

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Main menu